Portfolio Impact Analysis for the Therapeutic Development Branch (TDB), NCATS
Closed Solicitation Posted
- Solicitation number
- 75N95024Q00564
- Agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- Woman-Owned Small Business
Opportunity facts
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health (NIH), through its National Center for Advancing Translational Sciences (NCATS), is seeking a contractor to conduct a portfolio impact analysis of the Therapeutic Development Branch (TDB) from 2010 to the present. The goal is to capture key metrics and evaluate the program's research outcomes, including analyzing the economic and other quantitative and qualitative impact measures on further research, development, and healthcare. The contractor will be required to design a survey instrument, gather data, conduct analyses, and generate a report and presentation communicating the results. Evaluation criteria include Technical Approach, Key Personnel, Past Performance, and Price. Responses are due by September 16, 2024.
This commercial item acquisition is set aside exclusively for Women-Owned Small Businesses (WOSB). The period of performance is 9 months from the date of award, which is anticipated to be September 23, 2024. The government estimates the value of this firm, fixed-price award to be in the range typically associated with a small purchase.
Notice text
2 versions
Update #2 · Latest ·
Amendment 1 (9/11/2024): Adding Q&A as an attachment to the solicitation. See attached.
The Therapeutic Development Branch (TDB) in the intramural Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH) was established to enable preclinical development through collaborative partnerships. In alignment with accomplishing the Center’s mission, the Branch needs to conduct a portfolio impact analysis, from its inception in 2010 to present. The goal is to capture key metrics and evaluate the program’s research outcomes, including analyzing the economic and other quantitative and qualitative impact measures on further research and development and healthcare. TDB requires the expertise of a firm capable of conducting such types of specialized impact analyses of novel therapeutics and related technologies. The results of this analysis will be used by Branch leadership to inform future research policy and priorities.
See the attached Combined Synopsis/Solicitation, Statement of Work, and other attachments for complete requirement details.
Update #1 ·
The Therapeutic Development Branch (TDB) in the intramural Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH) was established to enable preclinical development through collaborative partnerships. In alignment with accomplishing the Center’s mission, the Branch needs to conduct a portfolio impact analysis, from its inception in 2010 to present. The goal is to capture key metrics and evaluate the program’s research outcomes, including analyzing the economic and other quantitative and qualitative impact measures on further research and development and healthcare. TDB requires the expertise of a firm capable of conducting such types of specialized impact analyses of novel therapeutics and related technologies. The results of this analysis will be used by Branch leadership to inform future research policy and priorities.
See the attached Combined Synopsis/Solicitation, Statement of Work, and other attachments for complete requirement details.
Files
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity